CT Financial Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

CT Financial Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$25.5K	Buy	603 +1	+0.2%	+$42	0.02%	333
2016 Q4	$23.4K	Buy	602 +1	+0.2%	+$40	0.01%	337
2016 Q3	$25.2K	Buy	601 +1	+0.2%	+$41	0.02%	330
2016 Q2	$22.2K	Sell	600 -1	-0.2%	-$39	0.01%	340
2016 Q1	$23K	Buy	601 +1	+0.2%	+$39	0.01%	359
2015 Q4	$30.3K	Buy	600 +3	+0.5%	+$148	0.02%	341
2015 Q3	$27.3K	Buy	597 +2	+0.3%	+$112	0.02%	352
2015 Q2	$34.7K	Buy	595 +1	+0.2%	+$57	0.02%	340
2015 Q1	$32.7K	Buy	594 +1	+0.2%	+$54	0.02%	342
2014 Q4	$29.8K	Buy	+593	New	+$29K	0.02%	285
2014 Q1	$32.7K	Buy	+594	New	+$25.4K	0.02%	342

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CT Financial Advisors's PBE Position: Q1 2017 in Review

CT Financial Advisors increased its Invesco Biotechnology & Genome ETF (PBE) stake by 0.17% in Q1 2017, buying an estimated $42 and bringing the position to 603 shares worth $25.5K. The position accounts for 0.02% of the portfolio, ranked #333.

CT Financial Advisors first reported a position in PBE in Q1 2014 and has held it in 11 quarters since. The position peaked at $34.7K in Q2 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q1 2017.

CT Financial Advisors held 603 shares of Invesco Biotechnology & Genome ETF worth $25.5K as of Q1 2017.
CT Financial Advisors bought 1 Invesco Biotechnology & Genome ETF share in Q1 2017, an estimated $42.
Invesco Biotechnology & Genome ETF made up 0.02% of CT Financial Advisors's portfolio in Q1 2017, its #333 holding.
CT Financial Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and has held it in 11 quarters since.
CT Financial Advisors's Invesco Biotechnology & Genome ETF position peaked at $34.7K in Q2 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.